View Future GrowthMonstarlab 과거 순이익 실적과거 기준 점검 0/6Monstarlab 의 수입은 연평균 -16.4%의 비율로 감소해 온 반면, IT 산업은 연평균 12%의 비율로 증가했습니다. 매출은 연평균 25.4%의 비율로 감소해 왔습니다.핵심 정보-16.39%순이익 성장률-9.42%주당순이익(EPS) 성장률IT 산업 성장률14.26%매출 성장률-25.37%자기자본이익률-22.55%순이익률-2.94%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • 17hFirst quarter 2026 earnings released: EPS: JP¥0.85 (vs JP¥3.11 loss in 1Q 2025)First quarter 2026 results: EPS: JP¥0.85 (up from JP¥3.11 loss in 1Q 2025). Revenue: JP¥1.95b (up 2.9% from 1Q 2025). Net income: JP¥55.0m (up JP¥192.8m from 1Q 2025). Profit margin: 2.8% (up from net loss in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.Reported Earnings • Apr 05Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 28Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024).공시 • Dec 27Monstarlab Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026Monstarlab Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: JP¥8.53 (vs JP¥53.64 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥8.53 (up from JP¥53.64 loss in 3Q 2024). Revenue: JP¥2.05b (down 7.6% from 3Q 2024). Net income: JP¥553.0m (up JP¥2.39b from 3Q 2024). Profit margin: 27% (up from net loss in 3Q 2024).Reported Earnings • Aug 16Second quarter 2025 earnings released: JP¥2.18 loss per share (vs JP¥162 loss in 2Q 2024)Second quarter 2025 results: JP¥2.18 loss per share (improved from JP¥162 loss in 2Q 2024). Revenue: JP¥1.88b (down 26% from 2Q 2024). Net loss: JP¥115.2m (loss narrowed 98% from 2Q 2024).모든 업데이트 보기Recent updatesReported Earnings • 17hFirst quarter 2026 earnings released: EPS: JP¥0.85 (vs JP¥3.11 loss in 1Q 2025)First quarter 2026 results: EPS: JP¥0.85 (up from JP¥3.11 loss in 1Q 2025). Revenue: JP¥1.95b (up 2.9% from 1Q 2025). Net income: JP¥55.0m (up JP¥192.8m from 1Q 2025). Profit margin: 2.8% (up from net loss in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.Reported Earnings • Apr 05Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 28Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024).공시 • Feb 27Monstarlab Inc., Annual General Meeting, Mar 31, 2026Monstarlab Inc., Annual General Meeting, Mar 31, 2026.분석 기사 • Feb 16We Think Monstarlab (TSE:5255) Is Taking Some Risk With Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Jan 09Why We Like The Returns At Monstarlab (TSE:5255)What are the early trends we should look for to identify a stock that could multiply in value over the long term...공시 • Dec 27Monstarlab Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026Monstarlab Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026분석 기사 • Nov 28There's Reason For Concern Over Monstarlab Inc.'s (TSE:5255) Massive 31% Price JumpThose holding Monstarlab Inc. ( TSE:5255 ) shares would be relieved that the share price has rebounded 31% in the last...Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: JP¥8.53 (vs JP¥53.64 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥8.53 (up from JP¥53.64 loss in 3Q 2024). Revenue: JP¥2.05b (down 7.6% from 3Q 2024). Net income: JP¥553.0m (up JP¥2.39b from 3Q 2024). Profit margin: 27% (up from net loss in 3Q 2024).분석 기사 • Oct 29Is Monstarlab (TSE:5255) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Aug 16Second quarter 2025 earnings released: JP¥2.18 loss per share (vs JP¥162 loss in 2Q 2024)Second quarter 2025 results: JP¥2.18 loss per share (improved from JP¥162 loss in 2Q 2024). Revenue: JP¥1.88b (down 26% from 2Q 2024). Net loss: JP¥115.2m (loss narrowed 98% from 2Q 2024).공시 • Jul 02Monstarlab Inc. announced that it has received ¥70.000184 million in fundingOn June 30, 2024. Monstarlab Inc. announced that it has closed the Transaction.공시 • Jun 13Monstarlab Inc. announced that it expects to receive ¥70.000184 million in fundingMonstarlab Inc. announced a private placement of 573,772 shares at a price of ¥122 per share for gross proceeds of ¥ 70,000,184 through third party allotment on June 13, 2025.The transaction includes participation from Hiroki Inagawa for 282,787 shares, Eiichi Matsushima for 245,902 shares, Tomoyuki Uno for 28,689 shares, Tatsuro Usui for 16,394 shares. The transaction is approved by board of the directors of the company. The transaction is expected to close on June 30, 2025.Reported Earnings • May 21First quarter 2025 earnings released: JP¥3.09 loss per share (vs JP¥9.91 loss in 1Q 2024)First quarter 2025 results: JP¥3.09 loss per share (improved from JP¥9.91 loss in 1Q 2024). Revenue: JP¥1.90b (down 40% from 1Q 2024). Net loss: JP¥137.0m (loss narrowed 60% from 1Q 2024).Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Auditor Yuko Miura was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 16+ 1 more updateMonstarlab Inc. to Report Q1, 2025 Results on May 15, 2025Monstarlab Inc. announced that they will report Q1, 2025 results on May 15, 2025Reported Earnings • Apr 05Full year 2024 earnings released: JP¥285 loss per share (vs JP¥70.06 loss in FY 2023)Full year 2024 results: JP¥285 loss per share (further deteriorated from JP¥70.06 loss in FY 2023). Revenue: JP¥10.0b (down 25% from FY 2023). Net loss: JP¥9.95b (loss widened 322% from FY 2023).New Risk • Mar 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥3.76b market cap, or US$25.1m).New Risk • Feb 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (JP¥3.94b market cap, or US$26.4m).New Risk • Feb 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥3.29b market cap, or US$21.7m).공시 • Feb 17Monstar Lab, Inc., Annual General Meeting, Mar 28, 2025Monstar Lab, Inc., Annual General Meeting, Mar 28, 2025.Reported Earnings • Feb 16Full year 2024 earnings released: JP¥285 loss per share (vs JP¥70.06 loss in FY 2023)Full year 2024 results: JP¥285 loss per share (further deteriorated from JP¥70.06 loss in FY 2023). Revenue: JP¥10.0b (down 25% from FY 2023). Net loss: JP¥9.95b (loss widened 322% from FY 2023).공시 • Jan 17+ 1 more updateMonstar Lab, Inc. to Report Q3, 2025 Results on Nov 14, 2025Monstar Lab, Inc. announced that they will report Q3, 2025 results on Nov 14, 2025New Risk • Jan 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥3.0b). Earnings have declined by 46% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (9.4% increase in shares outstanding). Market cap is less than US$100m (JP¥3.30b market cap, or US$21.0m).분석 기사 • Dec 05Monstar Lab, Inc. (TSE:5255) Could Be Riskier Than It LooksMonstar Lab, Inc.'s ( TSE:5255 ) price-to-sales (or "P/S") ratio of 0.3x may look like a pretty appealing investment...공시 • Sep 20Calvin Rodney Sylvinus Hart agreed to acquire Genieology from Monstar Lab, Inc. (TSE:5255) for approximately ¥240 million.Calvin Rodney Sylvinus Hart agreed to acquire Genieology from Monstar Lab, Inc. (TSE:5255) for approximately ¥240 million on September 19, 2024. A cash consideration of ¥241 million will be paid by the buyer. As part of consideration, ¥241 million is paid towards common equity of Genieology. As of December 31, 2023, Genieology reported total assets of ¥459 million and total common equity of ¥275 million. The expected completion of the transaction is September 30, 2024.Reported Earnings • Aug 19Second quarter 2024 earnings released: JP¥162 loss per share (vs JP¥32.03 loss in 2Q 2023)Second quarter 2024 results: JP¥162 loss per share (further deteriorated from JP¥32.03 loss in 2Q 2023). Revenue: JP¥2.54b (down 24% from 2Q 2023). Net loss: JP¥5.55b (loss widened 406% from 2Q 2023).Reported Earnings • May 18First quarter 2024 earnings released: JP¥9.91 loss per share (vs JP¥6.20 profit in 1Q 2023)First quarter 2024 results: JP¥9.91 loss per share (down from JP¥6.20 profit in 1Q 2023). Revenue: JP¥3.18b (down 13% from 1Q 2023). Net loss: JP¥340.0m (down 273% from profit in 1Q 2023).분석 기사 • Apr 11A Piece Of The Puzzle Missing From Monstar Lab, Inc.'s (TSE:5255) 32% Share Price ClimbMonstar Lab, Inc. ( TSE:5255 ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...분석 기사 • Feb 26Slammed 34% Monstar Lab, Inc. (TSE:5255) Screens Well Here But There Might Be A CatchMonstar Lab, Inc. ( TSE:5255 ) shares have had a horrible month, losing 34% after a relatively good period beforehand...공시 • Feb 16Monstar Lab, Inc., Annual General Meeting, Mar 28, 2024Monstar Lab, Inc., Annual General Meeting, Mar 28, 2024.공시 • Dec 06Monstar Lab, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024Monstar Lab, Inc. announced that they will report fiscal year 2023 results on Feb 14, 2024공시 • Dec 05+ 2 more updatesMonstar Lab, Inc. to Report Q2, 2024 Results on Aug 14, 2024Monstar Lab, Inc. announced that they will report Q2, 2024 results on Aug 14, 2024공시 • Sep 22Monstar Lab, Inc. (TSE:5255) agreed to acquire ExecutiveSearch.AI K.K.Monstar Lab, Inc. (TSE:5255) agreed to acquire ExecutiveSearch.AI K.K. on September 20, 2023. The consideration for 86 shares to be acquired in October 2023 is ¥413 million. The agreement states that the acquisition is completed in stages: 14 shares will be acquired in 2024, 14 shares in 2025, 14 shares in 2026, and 15 shares in 2027. The acquisition in 2027 completes the transaction, and all the issued shares of common stock will have been acquired. ExecutiveSearch.AI reported net assets of ¥69 million, total assets of ¥103 million, net sales of ¥190 million and operating profit of ¥11 million as at September 30, 2022. The advisory fees for this transaction is ¥12 million. The transaction is expected to close in 2027.New Risk • Aug 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.4b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (JP¥14.4b market cap, or US$98.4m).Board Change • Mar 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent External Director Chiamin Lai was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역Monstarlab가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TSE:5255 매출, 비용 및 순이익 (JPY Millions)날짜매출순이익일반관리비연구개발비31 Mar 267,849-2312,616031 Dec 257,795-4242,617030 Sep 257,891-1,9114,399030 Jun 258,060-4,3065,156031 Mar 258,724-9,7446,309031 Dec 2410,003-9,9477,220030 Sep 2411,179-9,0006,113030 Jun 2412,307-8,2566,454031 Mar 2412,887-2,8926,303031 Dec 2313,346-2,3556,196030 Sep 2314,255-1,4566,302030 Jun 2314,605-2225,954031 Mar 2314,800-6095,976031 Dec 2214,270-6745,627031 Dec 219,346-3,0534,245031 Dec 207,419-1,2743,0310양질의 수익: 5255 은(는) 현재 수익성이 없습니다.이익 마진 증가: 5255는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 5255은 수익성이 없으며 지난 5년 동안 손실이 연평균 16.4% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 5255의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 5255은 수익성이 없어 지난 해 수익 성장률을 IT 업계(15.7%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 5255는 현재 수익성이 없으므로 자본 수익률이 음수(-22.55%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YSoftware 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 01:28종가2026/05/20 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Monstarlab Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Shingo KumazawaDaiwa Securities Co. Ltd.
Reported Earnings • 17hFirst quarter 2026 earnings released: EPS: JP¥0.85 (vs JP¥3.11 loss in 1Q 2025)First quarter 2026 results: EPS: JP¥0.85 (up from JP¥3.11 loss in 1Q 2025). Revenue: JP¥1.95b (up 2.9% from 1Q 2025). Net income: JP¥55.0m (up JP¥192.8m from 1Q 2025). Profit margin: 2.8% (up from net loss in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Apr 05Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 28Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024).
공시 • Dec 27Monstarlab Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026Monstarlab Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026
Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: JP¥8.53 (vs JP¥53.64 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥8.53 (up from JP¥53.64 loss in 3Q 2024). Revenue: JP¥2.05b (down 7.6% from 3Q 2024). Net income: JP¥553.0m (up JP¥2.39b from 3Q 2024). Profit margin: 27% (up from net loss in 3Q 2024).
Reported Earnings • Aug 16Second quarter 2025 earnings released: JP¥2.18 loss per share (vs JP¥162 loss in 2Q 2024)Second quarter 2025 results: JP¥2.18 loss per share (improved from JP¥162 loss in 2Q 2024). Revenue: JP¥1.88b (down 26% from 2Q 2024). Net loss: JP¥115.2m (loss narrowed 98% from 2Q 2024).
Reported Earnings • 17hFirst quarter 2026 earnings released: EPS: JP¥0.85 (vs JP¥3.11 loss in 1Q 2025)First quarter 2026 results: EPS: JP¥0.85 (up from JP¥3.11 loss in 1Q 2025). Revenue: JP¥1.95b (up 2.9% from 1Q 2025). Net income: JP¥55.0m (up JP¥192.8m from 1Q 2025). Profit margin: 2.8% (up from net loss in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Apr 05Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 28Full year 2025 earnings released: JP¥5.95 loss per share (vs JP¥285 loss in FY 2024)Full year 2025 results: JP¥5.95 loss per share (improved from JP¥285 loss in FY 2024). Revenue: JP¥7.80b (down 22% from FY 2024). Net loss: JP¥337.0m (loss narrowed 97% from FY 2024).
공시 • Feb 27Monstarlab Inc., Annual General Meeting, Mar 31, 2026Monstarlab Inc., Annual General Meeting, Mar 31, 2026.
분석 기사 • Feb 16We Think Monstarlab (TSE:5255) Is Taking Some Risk With Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Jan 09Why We Like The Returns At Monstarlab (TSE:5255)What are the early trends we should look for to identify a stock that could multiply in value over the long term...
공시 • Dec 27Monstarlab Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026Monstarlab Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026
분석 기사 • Nov 28There's Reason For Concern Over Monstarlab Inc.'s (TSE:5255) Massive 31% Price JumpThose holding Monstarlab Inc. ( TSE:5255 ) shares would be relieved that the share price has rebounded 31% in the last...
Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: JP¥8.53 (vs JP¥53.64 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥8.53 (up from JP¥53.64 loss in 3Q 2024). Revenue: JP¥2.05b (down 7.6% from 3Q 2024). Net income: JP¥553.0m (up JP¥2.39b from 3Q 2024). Profit margin: 27% (up from net loss in 3Q 2024).
분석 기사 • Oct 29Is Monstarlab (TSE:5255) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Aug 16Second quarter 2025 earnings released: JP¥2.18 loss per share (vs JP¥162 loss in 2Q 2024)Second quarter 2025 results: JP¥2.18 loss per share (improved from JP¥162 loss in 2Q 2024). Revenue: JP¥1.88b (down 26% from 2Q 2024). Net loss: JP¥115.2m (loss narrowed 98% from 2Q 2024).
공시 • Jul 02Monstarlab Inc. announced that it has received ¥70.000184 million in fundingOn June 30, 2024. Monstarlab Inc. announced that it has closed the Transaction.
공시 • Jun 13Monstarlab Inc. announced that it expects to receive ¥70.000184 million in fundingMonstarlab Inc. announced a private placement of 573,772 shares at a price of ¥122 per share for gross proceeds of ¥ 70,000,184 through third party allotment on June 13, 2025.The transaction includes participation from Hiroki Inagawa for 282,787 shares, Eiichi Matsushima for 245,902 shares, Tomoyuki Uno for 28,689 shares, Tatsuro Usui for 16,394 shares. The transaction is approved by board of the directors of the company. The transaction is expected to close on June 30, 2025.
Reported Earnings • May 21First quarter 2025 earnings released: JP¥3.09 loss per share (vs JP¥9.91 loss in 1Q 2024)First quarter 2025 results: JP¥3.09 loss per share (improved from JP¥9.91 loss in 1Q 2024). Revenue: JP¥1.90b (down 40% from 1Q 2024). Net loss: JP¥137.0m (loss narrowed 60% from 1Q 2024).
Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Auditor Yuko Miura was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 16+ 1 more updateMonstarlab Inc. to Report Q1, 2025 Results on May 15, 2025Monstarlab Inc. announced that they will report Q1, 2025 results on May 15, 2025
Reported Earnings • Apr 05Full year 2024 earnings released: JP¥285 loss per share (vs JP¥70.06 loss in FY 2023)Full year 2024 results: JP¥285 loss per share (further deteriorated from JP¥70.06 loss in FY 2023). Revenue: JP¥10.0b (down 25% from FY 2023). Net loss: JP¥9.95b (loss widened 322% from FY 2023).
New Risk • Mar 24New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.3% average weekly change). Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risk Market cap is less than US$100m (JP¥3.76b market cap, or US$25.1m).
New Risk • Feb 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (JP¥3.94b market cap, or US$26.4m).
New Risk • Feb 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Negative equity (-JP¥4.8b). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥3.29b market cap, or US$21.7m).
공시 • Feb 17Monstar Lab, Inc., Annual General Meeting, Mar 28, 2025Monstar Lab, Inc., Annual General Meeting, Mar 28, 2025.
Reported Earnings • Feb 16Full year 2024 earnings released: JP¥285 loss per share (vs JP¥70.06 loss in FY 2023)Full year 2024 results: JP¥285 loss per share (further deteriorated from JP¥70.06 loss in FY 2023). Revenue: JP¥10.0b (down 25% from FY 2023). Net loss: JP¥9.95b (loss widened 322% from FY 2023).
공시 • Jan 17+ 1 more updateMonstar Lab, Inc. to Report Q3, 2025 Results on Nov 14, 2025Monstar Lab, Inc. announced that they will report Q3, 2025 results on Nov 14, 2025
New Risk • Jan 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥3.0b). Earnings have declined by 46% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Shareholders have been diluted in the past year (9.4% increase in shares outstanding). Market cap is less than US$100m (JP¥3.30b market cap, or US$21.0m).
분석 기사 • Dec 05Monstar Lab, Inc. (TSE:5255) Could Be Riskier Than It LooksMonstar Lab, Inc.'s ( TSE:5255 ) price-to-sales (or "P/S") ratio of 0.3x may look like a pretty appealing investment...
공시 • Sep 20Calvin Rodney Sylvinus Hart agreed to acquire Genieology from Monstar Lab, Inc. (TSE:5255) for approximately ¥240 million.Calvin Rodney Sylvinus Hart agreed to acquire Genieology from Monstar Lab, Inc. (TSE:5255) for approximately ¥240 million on September 19, 2024. A cash consideration of ¥241 million will be paid by the buyer. As part of consideration, ¥241 million is paid towards common equity of Genieology. As of December 31, 2023, Genieology reported total assets of ¥459 million and total common equity of ¥275 million. The expected completion of the transaction is September 30, 2024.
Reported Earnings • Aug 19Second quarter 2024 earnings released: JP¥162 loss per share (vs JP¥32.03 loss in 2Q 2023)Second quarter 2024 results: JP¥162 loss per share (further deteriorated from JP¥32.03 loss in 2Q 2023). Revenue: JP¥2.54b (down 24% from 2Q 2023). Net loss: JP¥5.55b (loss widened 406% from 2Q 2023).
Reported Earnings • May 18First quarter 2024 earnings released: JP¥9.91 loss per share (vs JP¥6.20 profit in 1Q 2023)First quarter 2024 results: JP¥9.91 loss per share (down from JP¥6.20 profit in 1Q 2023). Revenue: JP¥3.18b (down 13% from 1Q 2023). Net loss: JP¥340.0m (down 273% from profit in 1Q 2023).
분석 기사 • Apr 11A Piece Of The Puzzle Missing From Monstar Lab, Inc.'s (TSE:5255) 32% Share Price ClimbMonstar Lab, Inc. ( TSE:5255 ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...
분석 기사 • Feb 26Slammed 34% Monstar Lab, Inc. (TSE:5255) Screens Well Here But There Might Be A CatchMonstar Lab, Inc. ( TSE:5255 ) shares have had a horrible month, losing 34% after a relatively good period beforehand...
공시 • Feb 16Monstar Lab, Inc., Annual General Meeting, Mar 28, 2024Monstar Lab, Inc., Annual General Meeting, Mar 28, 2024.
공시 • Dec 06Monstar Lab, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024Monstar Lab, Inc. announced that they will report fiscal year 2023 results on Feb 14, 2024
공시 • Dec 05+ 2 more updatesMonstar Lab, Inc. to Report Q2, 2024 Results on Aug 14, 2024Monstar Lab, Inc. announced that they will report Q2, 2024 results on Aug 14, 2024
공시 • Sep 22Monstar Lab, Inc. (TSE:5255) agreed to acquire ExecutiveSearch.AI K.K.Monstar Lab, Inc. (TSE:5255) agreed to acquire ExecutiveSearch.AI K.K. on September 20, 2023. The consideration for 86 shares to be acquired in October 2023 is ¥413 million. The agreement states that the acquisition is completed in stages: 14 shares will be acquired in 2024, 14 shares in 2025, 14 shares in 2026, and 15 shares in 2027. The acquisition in 2027 completes the transaction, and all the issued shares of common stock will have been acquired. ExecutiveSearch.AI reported net assets of ¥69 million, total assets of ¥103 million, net sales of ¥190 million and operating profit of ¥11 million as at September 30, 2022. The advisory fees for this transaction is ¥12 million. The transaction is expected to close in 2027.
New Risk • Aug 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: JP¥14.4b (US$98.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (JP¥14.4b market cap, or US$98.4m).
Board Change • Mar 28Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent External Director Chiamin Lai was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.